Tissue potency determination through quantitative histomorphology analysis
AssigneeEnzyvant Therapeutics GmbH
InventorsAlex TRACY, Kristin MARKS, Michael Thomas JOHNSON, Thomas Stephen VILLANI
Life of this patent
Estimating the term…
Loading patent…
AssigneeEnzyvant Therapeutics GmbH
InventorsAlex TRACY, Kristin MARKS, Michael Thomas JOHNSON, Thomas Stephen VILLANI
Estimating the term…
Systems and methods for performing quantitative histopathology analysis for determining tissue potency are disclosed. According to some embodiments, a method training a tissue classifier is provided. According to the method, training the tissue classifier includes generating feature fingerprints of detected nuclei within slide images in a control library and clustering the slide images based on their corresponding feature fingerprints. According to some embodiments, a method for utilizing the trained tissue classifier is provided. According to the method, the trained tissue classifier determines whether tissue in an unknown slide image corresponds to slide images clustered during the training of the tissue classifier.
1-60. (canceled)
method of training a tissue classifier for performing quantitative histopathological assessment, comprising:
The method according to claim 1, wherein the tissue classifier is capable of determining potency or the quality of the tissue for transplantation into a subject.
The method according to claim 2, wherein the tissue is thymus tissue.
The method according to claim 3, wherein the tissue is allogeneic cultured postnatal thymus tissue-derived product slices for implantation into a human subject.
The method according to claim 4, wherein the human subject is suffering from complete DiGeorge syndrome associated with 22q11.2 deletion;
The method according to claim 2, wherein the tissue classifier determines potency or quality of a tissue for transplantation into a subject of an unknown tissue for transplantation by generating feature fingerprints of detected nuclei within slide images in a control library and clustering the slide images based on their corresponding feature fingerprints.
The method according to claim 6, wherein the unknown tissue is thymus tissue.
The method according to claim 7, where the thymus tissue has been subjected to a culturing process in a thymus organ medium for a period of time to partially deplete the thymus tissue of thymocytes.
The method according to claim 8, wherein the period of time is up to 21 days.
The method according to claim 8, wherein the period of time is from about 12 to about 21 days.
The method according to claim 8, wherein the period of time is from about 5 to about 9 days.
The method according to claim 8, wherein the culturing process preserves the functional architecture of the thymic stroma.
The method according to claim 12, wherein the thymic stroma comprises thymic epithelial cells and fibroblasts.
The method according to claim 1, wherein the tissue is selected from the group consisting of vascular tissue, skin tissue, hepatic tissue, pancreatic tissue, neural tissue, urogenital tissue, gastrointestinal tissue, skeletal tissue including bone and cartilage, adipose tissue, connective tissue including tendons and ligaments, amniotic tissue, chorionic tissue, dura, pericardia, muscle tissue, glandular tissue, facial tissue, ophthalmic tissue.
The method according to claim 1, wherein the feature fingerprint is generated from measurements comprising numerical values of an area of the detected nucleus, a perimeter of the detected nucleus, an integrated density of the detected nucleus, and a circularity of the detected nucleus.
A method for performing quantitative histopathological assessment of an unclassified slide image of a tissue, comprising:
The method according to claim 16, wherein the feature fingerprint is capable of determining potency or the quality of the tissue for transplantation into a subject.
The method according to claim 17, wherein the tissue is thymus tissue.
The method according to claim 18, wherein the tissue is allogeneic cultured postnatal thymus tissue-derived product slices for implantation into a human subject.
The method according to claim 19, wherein the human subject is suffering from complete DiGeorge syndrome associated with 22q11.2 deletion;
The method according to claim 17, wherein the feature fingerprint determines potency or quality of the tissue for transplantation into a subject of an unknown tissue by generating feature fingerprints of detected nuclei within slide images in a control library and clustering the slide images based on their corresponding feature fingerprints.
The method according to claim 21, wherein the unknown tissue is thymus tissue.
The method according to claim 22, where the thymus tissue has been subjected to a culturing process in a thymus organ medium for a period of time to partially deplete the thymus tissue of thymocytes.
The method according to claim 23, wherein the period of time is up to 21 days.
The method according to claim 23, wherein the period of time is from about 12 to about 21 days.
The method according to claim 23, wherein the period of time is from about 5 to about 9 days.
The method according to claim 23, wherein the culturing process preserves the functional architecture of the thymic stroma.
The method according to claim 27, wherein the thymic stroma comprises thymic epithelial cells and fibroblasts.
The method according to claim 16, wherein the tissue is selected from the group consisting of vascular tissue, skin tissue, hepatic tissue, pancreatic tissue, neural tissue, urogenital tissue, gastrointestinal tissue, skeletal tissue including bone and cartilage, adipose tissue, connective tissue including tendons and ligaments, amniotic tissue, chorionic tissue, dura, pericardia, muscle tissue, glandular tissue, facial tissue, ophthalmic tissue.
The method according to claim 17, wherein the feature fingerprint is generated from measurements comprising numerical values of an area of the detected nucleus, a perimeter of the detected nucleus, an integrated density of the detected nucleus, and a circularity of the detected nucleus.
A system for classifying objects within digital images of tissue, comprising:
The system according to claim 31, wherein the system is capable of determining potency or the quality of a tissue for transplantation into a subject.
The system according to claim 32, wherein the tissue is thymus tissue.
The system according to claim 33, wherein the thymus tissue is allogeneic cultured postnatal thymus tissue-derived product slices for implantation into a human subject.
The system according to claim 34, wherein the human subject is suffering from complete DiGeorge syndrome associated with 22q11.2 deletion;
The system according to claim 31, wherein the system classifies potency or quality of a tissue for transplantation into a subject of an unknown tissue by generating feature fingerprints of detected nuclei within slide images in a control library and clustering the slide images based on their corresponding feature fingerprints.
The system according to claim 36, wherein the unknown tissue is thymus tissue.
The system according to claim 37, where the thymus tissue has been subjected to a culturing process in a thymus organ medium for a period of time to partially deplete the thymus tissue of thymocytes.
The system according to claim 38, wherein the period of time is up to 21 days.
The system according to claim 38, wherein the period of time is from about 12 to about 21 days.
The system according to claim 38, wherein the period of time is from about 5 to about 9 days.
The system according to claim 38, wherein the culturing process preserves the functional architecture of the thymic stroma.
The system according to claim 42, wherein the thymic stroma comprises thymic epithelial cells and fibroblasts.
The system according to claim 31, wherein the tissue is selected from the group consisting of vascular tissue, skin tissue, hepatic tissue, pancreatic tissue, neural tissue, urogenital tissue, gastrointestinal tissue, skeletal tissue including bone and cartilage, adipose tissue, connective tissue including tendons and ligaments, amniotic tissue, chorionic tissue, dura, pericardia, muscle tissue, glandular tissue, facial tissue, ophthalmic tissue.
The system according to claim 36, wherein the feature fingerprint is generated from measurements comprising numerical values of an area of the detected nucleus, a perimeter of the detected nucleus, an integrated density of the detected nucleus, and a circularity of the detected nucleus.
A classifier, comprising:
The classifier according to claim 46, wherein the system is capable of determining potency or the quality of a tissue for transplantation into a subject.
The classifier according to claim 47, wherein the tissue is thymus tissue.
The classifier according to claim 48, wherein the thymus tissue is allogeneic cultured postnatal thymus tissue-derived product slices for implantation into a human subject.
The classifier according to claim 49, wherein the human subject is suffering from complete DiGeorge syndrome associated with 22q11.2 deletion;
The classifier according to claim 46, wherein the system classifies potency of an unknown tissue by generating feature fingerprints of detected nuclei within slide images in a control library and clustering the slide images based on their corresponding feature fingerprints.
The classifier according to claim 51, wherein the unknown tissue is thymus tissue.
The classifier according to claim 52, where the thymus tissue has been subjected to a culturing process in a thymus organ medium for a period of time to partially deplete the thymus tissue of thymocytes.
The classifier according to claim 53, wherein the period of time is up to 21 days.
The classifier according to claim 53, wherein the period of time is from about 12 to about 21 days.
The classifier according to claim 53, wherein the period of time is from about 5 to about 9 days.
The classifier according to claim 53, wherein the culturing process preserves the functional architecture of the thymic stroma.
The classifier according to claim 57, wherein the thymic stroma comprises thymic epithelial cells and fibroblasts.
The classifier according to claim 46, wherein the tissue is selected from the group consisting of vascular tissue, skin tissue, hepatic tissue, pancreatic tissue, neural tissue, urogenital tissue, gastrointestinal tissue, skeletal tissue including bone and cartilage, adipose tissue, connective tissue including tendons and ligaments, amniotic tissue, chorionic tissue, dura, pericardia, muscle tissue, glandular tissue, facial tissue, ophthalmic tissue.
The classifier according to claim 46, wherein the feature fingerprint is generated from measurements comprising numerical values of an area of the detected nucleus, a perimeter of the detected nucleus, an integrated density of the detected nucleus, and a circularity of the detected nucleus.
Dependencies are inferred from the claim text.